Adding the targeted drug savolitinib to osimertinib, sold as Tagrisso, significantly delayed disease progression compared with osimertinib alone in previously untreated patients with EGFR-mutated, MET-overexpressing non-small cell lung cancer, according to topline results announced by HUTCHMED from the phase 3 SANOVO trial.
The relevance for American patients is real but indirect, and the qualifiers matter more than the headline. SANOVO was conducted entirely in China. The combination is not approved in the United States for this use. No efficacy figures have been released. Nothing about this changes what a U.S. oncologist can prescribe this week.
What it does is strengthen a case that has been building about a specific resistance problem, and it raises a question worth asking at an appointment: whether a patient's tumor has been tested for MET.
The Trial and the Comparison That Matters
About 10 to 15 percent of non-small cell lung cancer patients in the United States and Europe have EGFR mutations, a figure that rises to roughly 30 to 40 percent in Asia. For those patients osimertinib is a standard first treatment. It works well, and then it stops working. MET amplification or overexpression is one of the most common reasons why.
Savolitinib, sold as Orpathys, blocks MET. The logic of the combination is to suppress both pathways at once rather than waiting for the second one to drive resistance.
SANOVO tested that idea in patients who had never been treated. It randomly assigned 326 patients one-to-one to receive osimertinib plus either savolitinib or a placebo, with the savolitinib dose set by body weight. The combination beat osimertinib alone on the primary endpoint of investigator-assessed progression-free survival, meaning time before the cancer grew or spread, in both the high MET group and the overall trial population. The companies also reported an encouraging clinical benefit on overall survival, a secondary endpoint, with follow-up continuing. The reported safety profile was consistent with what is already known about each drug.
Giving both drugs from the start is a different bet from adding the second one later. It exposes every patient to the side effects and cost of two targeted drugs, including those whose cancer might have been controlled for a long time on osimertinib alone. Whether that trade is worth it depends on numbers the companies have not released.
That first-line design is what separates SANOVO from the global SAFFRON trial reported in mid-August, which tested the same combination in patients whose cancer had already progressed on osimertinib and compared it with platinum-based chemotherapy. SAFFRON showed improvements in both progression-free and overall survival, and AstraZeneca described the result as the first for a global phase 3 study in that setting.
Numbers Nobody Has Seen Yet
This is a topline announcement from a company press release. It is not a published study, it has not been peer reviewed, and it has not been presented at a medical meeting. No survival curves, hazard ratios, median durations, or adverse event rates have been released.
Statistically significant and clinically meaningful is the language companies use before data exist publicly. It can describe a difference of several months or a difference of a few weeks. Until the full dataset appears at a congress or in a journal, there is no way for anyone outside the trial to judge magnitude.
Two further limits come up front. SANOVO enrolled patients in China, and treatment patterns, prior therapy, and population genetics can all differ from a U.S. population. And progression-free survival is a measure of tumor control, not of how long people live. The overall survival result was described as encouraging rather than statistically established.
Weiguo Su, chief executive and chief scientific officer of HUTCHMED, said the findings validate the company's strategy on MET-driven disease. Yi-Long Wu of Guangdong Provincial People's Hospital, the lead principal investigator, said the results show a benefit that "could reshape primary treatment strategy for this distinct patient population."
MET Testing Is the Part U S Patients Can Act On
Whatever regulators eventually decide, none of this reaches a patient who has not been tested for the biomarker.
MET status is not always assessed at diagnosis, and it is frequently assessed only after a patient progresses on an EGFR inhibitor, if at all. Testing methods also differ. MET amplification, meaning extra copies of the gene, and MET overexpression, meaning excess protein, are detected by different assays, and which one a lab ran affects what a result means.
MedicalDaily has previously reported on the FDA's list of authorized companion diagnostics, which pairs specific tests with specific drugs.
The useful questions at an oncology visit are narrow. Has comprehensive biomarker testing been done on the tumor, and was MET included? If a patient is on osimertinib and the cancer has progressed, was the tumor retested at progression rather than relying on the original result? And is a clinical trial of a MET-directed combination open nearby?
Nobody should change or stop an EGFR inhibitor based on a press release about a trial conducted in another country.
Where This Sits in the U S Approval Path
The combination was approved in China in June 2025, on the strength of the SACHI trial, for patients with EGFR-mutated non-small cell lung cancer and MET amplification whose disease progressed on EGFR inhibitor therapy. The FDA has not approved the combination.
SAFFRON is the trial most likely to support a U.S. filing, because it is global and showed an overall survival benefit. SANOVO extends the case into first-line treatment, but a China-only trial is generally supporting evidence rather than the primary basis for a U.S. approval.
Full data from both trials are expected at forthcoming medical meetings. No filing date, review timeline, or U.S. pricing has been announced, and none should be assumed. Even after approval, access to a newly approved oncology combination usually runs through prior authorization, and patient assistance programs exist for people who hit coverage barriers.
For now, the practical takeaway for a household facing EGFR-mutated lung cancer is smaller than the headline suggests and more actionable: ask about biomarker testing, ask whether retesting at progression is appropriate, and ask about trials.
Key Questions Answered
What was announced? HUTCHMED reported that savolitinib plus osimertinib significantly improved progression-free survival versus osimertinib alone in 326 previously untreated patients with EGFR-mutated, MET-overexpressing lung cancer in the phase 3 SANOVO trial.
Is this combination available in the United States? No. It is approved in China for a different, later-line setting. The FDA has not approved it.
How strong is the evidence? Preliminary. This is a company topline announcement with no published data, no peer review, and no presentation at a medical meeting.
What is the difference between SANOVO and SAFFRON? SANOVO tested the combination as first-line treatment in China against osimertinib alone. SAFFRON was a global trial in patients who had already progressed on osimertinib, compared against chemotherapy.
Does progression-free survival mean people live longer? Not necessarily. It measures time before the cancer grows or spreads. Overall survival was described as showing an encouraging benefit, which is weaker than an established one.
What should a patient with EGFR lung cancer do now? Ask whether comprehensive biomarker testing included MET, whether retesting at progression is appropriate, and whether relevant trials are open.
Should anyone change treatment because of this? No. Do not stop or alter an EGFR inhibitor based on trial results announced by press release in another country.
